HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2003.030825v1 50/9/1623    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Steimer, W. Articles by Leucht, S. Search for Related Content PubMed PubMed Citation Articles by Steimer, W. Articles by Leucht, S. Related Collections Molecular Diagnostics and Genetics Proteomics and Protein Markers Drug Monitoring and Toxicology Automation and Analytical Techniques

Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers

¹ Institut für Klinische Chemie und Pathobiochemie, and ² Psychiatrische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
³ Bezirkskrankenhaus Haar, Haar, Germany.

^aAddress correspondence to this author at: Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, D-81675 Munich, Germany. Fax 49-89-4140-4875; e-mail Steimer{at}KlinChem.med.TU-Muenchen.de.

Background: Recently, new polymorphisms were described in connection with intermediate and ultrarapid CYP2D6 metabolism. These may allow a much desired prediction of metabolic activity within the extensive metabolizer group. The functional consequences are still being discussed with few data available for clinical patients.

Methods: We conducted a prospective, blinded two-center study seeking correlations between CYP2C19 (*2,*3, and *4; conventional PCR) and CYP2D6 genotypes (*1 to *10, *35, and *41; real-time and multiplex PCR) and drug concentrations (Emit® and HPLC) in 50 Caucasians receiving amitriptyline (AT; 75 mg twice a day).

Results: Eighteen CYP2C19 heterozygotes (*1/*2) had higher AT (P = 0.033) and lower nortriptyline (NT; P = 0.059) concentrations than 30 homozygotes (*1/*1). For CYP2D6, we calculated two new indices, i.e., the allele-specific change of concentration on identical background (ASCOC) and a quantitative functional gene dose. The ASCOC describes the change in NT concentration attributable to a mutant allele compared with the wild type. We found significantly higher concentrations for alleles *4 (95.6%; P <0.0001), *10 (63.3%; P <0.001), and *41 (39.8%; P <0.0001) but not for *2 and *35. Assigning of semiquantitative gene doses of 0, 0.5, or 1 to each allele instead of applying the current classification system (predicted phenotypes: 3 intermediate metabolizers, 46 extensive metabolizers, and 1 ultrarapid metabolizer) produced significant NT concentration differences: gene doses of 0.5 (n =3), 1 (n = 14), 1.5 (n = 11), 2 (n = 21) and 3 (n = 1; P <0.00001).

Conclusions: AT and NT concentrations can be predicted within the group of CYP2D6 extensive metabolizers. The ASCOC provides substantial advantages compared with current methods of analysis. CYP2D6 but not CYP2C19 correlates with the sum of both concentrations used to guide AT therapy.

The following articles in journals at HighWire Press have cited this article:

				N. von Ahsen and M. Oellerich Chip-Based Genotyping: Translation of Pharmacogenetic Research to Clinical Practice Clin. Chem., July 1, 2007; 53(7): 1186 - 1187. [Full Text] [PDF]

				J. K. Blievernicht, E. Schaeffeler, K. Klein, M. Eichelbaum, M. Schwab, and U. M. Zanger MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms Clin. Chem., January 1, 2007; 53(1): 24 - 33. [Abstract] [Full Text] [PDF]

				J. E. Kootstra-Ros, M. J. M. Van Weelden, J. W. J. Hinrichs, P. A. G. M. De Smet, and J. van der Weide Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J. Clin. Pharmacol., November 1, 2006; 46(11): 1320 - 1327. [Abstract] [Full Text] [PDF]

				S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]

				B. Laika, S. Leucht, and W. Steimer ABCB1 (P-Glycoprotein/MDR1) Gene G2677T/A Sequence Variation (Polymorphism): Lack of Association with Side Effects and Therapeutic Response in Depressed Inpatients Treated with Amitriptyline. Clin. Chem., May 1, 2006; 52(5): 893 - 895. [Full Text] [PDF]

				W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, J. Popp, B. Messner, W. Kissling, and S. Leucht Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy Clin. Chem., February 1, 2005; 51(2): 376 - 385. [Abstract] [Full Text] [PDF]

				R. Valdes Jr and M. W. Linder Fine-Tuning Pharmacogenetics: Paradigm for Linking Laboratory Results to Clinical Action Clin. Chem., September 1, 2004; 50(9): 1498 - 1499. [Full Text] [PDF]